- Denmark’s H. Lundbeck (OTC:HLUKF) snaps up Abide Therapeutics and adds differentiated chemo-proteomic discovery platform and a US-based research hub.
- Abide's lead program, ABX-1431, is a selective inhibitor of serine hydrolase monoacylglycerol lipase/MGLL and is designed to increase the power of endocannabinoid signaling to restore homeostatic balance in the central nervous system.
- Lundbeck will pay $250M upfront and up to $150M in milestones
- The transaction is expected to close by Q2 2019.